Abstracts tagged "Sjogren’s syndrome and transcriptional regulation"

Abstract Number: 2978 • 2014 ACR/ARHP Annual Meeting
Characterization of the Sjögren’s Syndrome Intergenic Non-Coding RNA 1 (SSINCR1)
John A. Ice¹, He Li^2,3, Indra Adrianto², Mikhail G. Dozmorov⁴, Astrid Rasmussen⁵, Graham B. Wiley¹, Jennifer A. Kelly¹, Kimberly S. Hefner⁶, Donald U. Stone⁷, Raj Gopalakrishnan⁸, David M. Lewis⁹, Stephen Young⁹, Michael D. Rohrer⁸, Juan-Manuel Anaya¹⁰, Swamy Venuturupalli¹¹, Barbara M. Segal¹², Nelson L. Rhodus¹³, Lida Radfar¹⁴, Michael H. Weisman¹⁵, Judith A. James^16,17, Courtney G. Montgomery¹⁸, R. Hal Scofield^19,20,21, Patrick M. Gaffney¹, Linda F. Thompson²², A. Darise Farris²³, Susan Kovats¹, Jonathan D. Wren¹, Kathy L. Sivils²⁴ and Christopher J. Lessard²⁵, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁷Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁹College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹³University of Minnesota, Minneapolis, MN, ¹⁴College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁶Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²⁰College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²²Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²³Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ²⁴Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁵825 N.E. 13th St., Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Sjögren’s syndrome (SS) is a common autoimmune disorder characterized by immune-mediated exocrine gland destruction and systemic inflammatory responses that contribute to clinical heterogeneity. Widespread…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].